NCT00182559View on ClinicalTrials.gov

The Vienna Prograf and Endothelial Progenitor Cell Study

PHASE4CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
End Stage Renal Disease
Interventions
DRUG

Ciclosporin

Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.

DRUG

Tacrolimus

Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT00182559 - The Vienna Prograf and Endothelial Progenitor Cell Study | Biotech Hunter | Biotech Hunter